Company
Novartis
Official Name: Novartis AG
Headquarters: Basel, Switzerland
Founded: March 1996
Employees: 104,323
Market Cap
CHF179.80 Billion
CHF as of Jan. 1, 2023
US$194.45 Billion
Switzerland
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Pfizer
|
$287.63 B |
|
AbbVie
|
$285.80 B |
|
Merck
|
$281.30 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Stocks & Indices
Novartis AG has the following listings and related stock indices.
Stock: SIX: NOVN
Stock: NYSE: NVS
Stock: BCBA: NVS
Stock: Bovespa: N1VS34
Stock: FSX: NOTA
Stock: OTC: NVSEF
Stock: SIX: NOVNEE
Product & Services
Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...)
Key People
Founder(s): Johann Rudolf Alexander Clavel
Vasant Narasimhan (CEO)
Financials
Revenue: US$49.89 billion (2020)
Operating income: US$10.15 billion (2020)
Net income: US$8.07 billion (2020)
Total assets: US$132.06 billion (2020)
Total equity: US$56.67 billion (2020)